Project Grant R01AI184476
Award Date 8/7/26
Completion Date 7/31/31
Dollars Obligated $862K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Grafton, MA 01536, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $859,278 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate discovery of narrow-spectrum antibiotics targeting Borrelia burgdorferi, the causative agent of Lyme disease. Narrow-spectrum agents that affect only the target bacterium avoid resistance propagation in off-target bacteria, microbiome...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $165,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 1, 2025, with a completion date of June 30, 2027. This award funds the development of an improved transposon mutagenesis system for comprehensive genetic analysis of Borrelia burgdorferi, the causative agent of Lyme disease. The primary deliverables...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $100,228 on December 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of G-quadruplex DNA structures in the antigenic variation mechanism of Borrelia burgdorferi, the causative agent of Lyme disease. The research addresses the molecular mechanism by which B. burgdorferi evades host adaptive immune defenses through antigenic variation—reshaping outer...
- The National Institute of Allergy and Infectious Diseases awarded $314,363 to Keylicon Biosciences Inc. on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a multivalent self-amplifying RNA (SARNA) vaccine against Lyme disease. The recipient will develop a SARNA vaccine encoding Borrelia antigens derived from diverse species to provide broad protection against Lyme disease, the most common vector-borne illness in North America. The vaccine...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $3.32 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 19, 2025, to support research on the microbial determinants of excessive inflammation and severe Lyme disease through August 31, 2029. The research addresses the lack of biomarkers to identify patients at greater risk for adverse outcomes...
- The National Institute of Allergy and Infectious Diseases awarded Bioscience Development Inc. $210,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance proteomics research on post-treatment Lyme disease syndrome (PTLDS). The recipient will conduct cerebrospinal fluid (CSF) proteome analysis using mass spectrometry to identify protein biomarkers associated with PTLDS, the chronic condition affecting 10–20 percent of Lyme disease patients...
- The National Institute of Allergy and Infectious Diseases awarded the University of Toledo $768,796 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify immunoprotective antigens for preventing Lyme disease caused by Borrelia burgdorferi. The research will evaluate attenuated bacterial mutants as vaccine candidates, building on the recipient's prior identification of a BB strain lacking a chemotaxis-related gene that is rapidly cleared from...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded $453,750 to Massachusetts General Hospital on July 13, 2026, to identify and characterize genes in Borrelia burgdorferi that influence dissemination of Lyme disease in vertebrate hosts. The research focuses on microbial genetic determinants that drive dissemination—the progression from localized infection to severe systemic disease affecting the nervous system, joints, or...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $229,500 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the antimicrobial network orchestrated by the noncanonical IMD (immune deficiency) pathway in ticks. The research examines how the tick immune system restricts colonization and survival of Borrelia burgdorferi, the spirochete that causes Lyme disease. Ticks possess core signaling components of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $457,875 on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate independent gene regulation by the Borrelia burgdorferi FUR ortholog BosR. The research examines how BosR, the sole member of the ferric uptake regulator family in Borrelia burgdorferi (the Lyme disease spirochete), regulates genes outside the well-studied rpoN/rpoS...